Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, and at the Department of Pharmacy, University of Patras, Greece. He has been conducting laboratory and clinical research on e-cigarettes as a principal investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has presented his research findings at major international scientific congresses and his research was used in preparing the regulatory framework on e-cigarettes by the European Union. As of 2016, he has published more than 40 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes.Gene Gillman received his PhD in Chemistry from Wake Forest University, Winston-Salem, North Carolina. He is now Laboratory Director at Enthalpy Analytical, Inc., Durham, North Carolina. He has considerable experience in investigating the constituents and chemistry of tobacco smoke, and in developing and validating relevant LC, LC-MS, GC-MS, and biological based test methods. He brings experience from both the cigarette manufacturing and tobacco testing contract research organization perspectives to his work with domestic and international study groups and trade organizations.Stephen Hecht received his PhD from the Massachusetts Institute of Technology and is currently the Wallin Land Grant Professor of Cancer Prevention, Department of Laboratory Medicine and Pathology at the University of Minnesota. His research interests include mechanisms of metabolic activation and DNA modification by carcinogens in tobacco products and the human environment, and application of this knowledge to cancer prevention. His laboratory focuses on the properties of carcinogenic nitrosamines, polycyclic aromatic hydrocarbons, and aldehydes. Using state-of-the-art mass spectrometry and related techniques, he has developed analytical methods for quantitation of carcinogen and toxicant metabolites and DNA adducts in laboratory animals and in human urine, blood, and tissues. These biomarkers are applied in collaborative clinical and epidemiologic studies. Stable isotope-labelled carcinogens and their analogues are employed in tobacco users to track individual differences in metabolism. The effects of naturally occurring potentially cancer-chemopreventive compounds on carcinogen metabolism in humans are also investigated. Among his numerous distinctions, Dr. Hecht has authored or co-authored over 700 peer-reviewed research publications, is Editor-in-Chief of Chemical Research in Toxicology, and in 2014 was named an American Association for the Advancement of Science Fellow.Riccardo Polosa is the Director of the Institute for Internal Medicine and Clinical Immunology of the University of Catania, Italy. He is also in charge of the University's Centre for Tobacco Research (CPCT) and is Honorary Professor of Medicine at University of Southampton, UK. An internationally recognized leader in the field of clinical bronchoprovocation (airway-challenge studies), he has published more than 250 peer-reviewed articles and books, mainly on respiratory medicine, clinical immunology, and tobacco addiction. After many years of service as President of the Italian Anti-Smoking League (LIAF: Lega Italiana Anti Fumo), he now serves as its Chief Scientific Advisor.